InhaleRx Company Description

InhaleRx Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia.

It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD).

The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021.

InhaleRx Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.

InhaleRx Limited

Country	Australia
Founded	2016
Industry	Medical Devices
Sector	Healthcare
CEO	Darryl Davies

Contact Details

Address: 505 Little Collins Street Melbourne, 3000 Australia
Phone	61 3 8678 4091
Website	inhalerx.com.au

Stock Details

Ticker Symbol	IRX
Exchange	Australian Securities Exchange
Fiscal Year	January - December
Reporting Currency	AUD
ISIN Number	AU0000179475
SIC Code	3841

Key Executives

Name	Position
Darryl Davies B.Sc.	Chief Executive Officer
Dr. Robert Jenny B.A., B.Sc., Ph.D.	Chief Scientific Officer
James Stephen Barrie CPA	Company Secretary
Greg Hammond	Chief Financial Officer
Srinivasa Rao Suryadevara	Executive Vice President